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Background: The unfolded protein response (UPR) is one of the pathways triggered to ensure quality control of
the proteins assembled in the endoplasmic reticulum (ER) when cell homeostasis is compromised. This mechanism
is primarily composed of three transmembrane proteins serving as stress sensors: PKR-like ER kinase (PERK), activating
transcription factor 6 (ATF6), and inositol-requiring enzyme 1 (IRE1). These three proteins’ synergic action elicits
translation and transcriptional downstream pathways, leading to less protein production and activating genes that
encode important proteins in folding processes, including chaperones. Previous reports showed that viruses have
evolved mechanisms to curtail or customize this UPR signaling for their own benefit. However, HIV infection’s effect on
the UPR has scarcely been investigated.
Methods: This work investigated UPR modulation by HIV infection by assessing UPR-related protein expression under
in vitro and in vivo conditions via Western blotting. Antiretroviral (ARV) drugs’ influence on this stress response was also
considered.
Results: In in vitro and in vivo analyses, our results confirm that HIV infection activates stress-response components and
that ARV therapy contributes to changes in the UPR’s activation profile.
Conclusions: This is the first report showing UPR-related protein expression in HIV target cells derived directly from
HIV-infected patients receiving different ARV therapies. Thus, two mechanisms may occur simultaneously: interference
by HIV itself and the ARV drugs’ pharmacological effects as UPR activators. New evidence of how HIV modulates the
UPR to enhance its own replication and secure infection success is also presented.
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The unfolded protein response (UPR) is a mechanism
elicited whenever protein folding is compromised inside
the endoplasmic reticulum (ER) [1]. In the last few years,
interest in the UPR signaling network has been increas-
ing due to the implication of ER stress mechanisms in a
wide range of pathologies, including infections, ischemic
injury, neurodegenerative disorders, metabolic diseases,
and neoplasias [2, 3]. Under stress conditions, UPR activa-
tion is essential to restore protein-folding homeostasis;
however, if the damage to the cell is highly severe, the
chronic ER stress and UPR signaling lead to cell apoptosis* Correspondence: aguinaldo.pinto@ufsc.br
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creativecommons.org/publicdomain/zero/1.0/[1]. In mammals in particular, unfolded proteins are recog-
nized in the ER lumen by the chaperone molecule im-
munoglobulin heavy chain-binding protein (GRP78/BiP),
which dissociates from three transmembrane proteins:
PKR-like ER kinase (PERK), activating transcription factor
6 (ATF6), and inositol-requiring enzyme 1 (IRE1) [4]. The
synergic action of these three proteins, also known as UPR
sensors, leads to translation and transcriptional down-
stream pathways that lead to less protein production and
to the activation of genes that encode important proteins
in folding processes, such as chaperones [1, 4].
The presence of unfolded proteins inside the ER lumen
can result from many different physiological conditions,
such as cell development and differentiation, high produc-
tion of secreted proteins, genetic mutation, or oxidative
stress, or may even be a response against certain pathogens,icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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may be specifically caused by the production of new viral
particles due to the high load of viral protein production in
the ER during infection. However, certain downstream ef-
fectors are not necessarily beneficial for viral replication,
e.g., protein degradation by the ubiquitin- and proteasome-
dependent process known as ER-associated degradation
(ERAD) or apoptosis induction [5, 6]. Nonetheless, viruses
are also capable of avoiding activation of several mecha-
nisms in the UPR pathway, which shows their ability to
modulate this cellular stress response both to promote cell
survival during efficient viral replication and to create an
environment more favorable for replication [7].
The effect of HIV infection on the UPR pathway has
scarcely been investigated [8, 9]. Regarding HIV target
cells in particular, an in vitro study using the Jurkat
CD4+ T-cell line and U1 pro-monocytic cells showed
that HIV is responsible for inducing ATF4 transcription
and translation, leading to an accumulation of this factor
during the acute phase of infection [10]. This report also
indicated that ATF4 triggers the reactivation of HIV rep-
lication in infected cells through a mechanism mediated
by the viral protein Tat, suggesting that the ER stress
events that lead to high expression of ATF4 may be rele-
vant for the end of viral latency. Additionally, reports
have shown that the protease inhibitors used as part of
ARV therapy are responsible for pharmacological activa-
tion of the UPR pathway in vitro [11–14]. However, des-
pite the known pharmacological effects of ARV drugs
against HIV, the possible UPR mechanisms modulated
by HIV in the host cell are not completely elucidated.
Thus, we were interested in investigating UPR pathway
modulation by HIV infection via assessment of the ex-
pression of UPR-related proteins under in vitro and
in vivo conditions. We also considered the influence of
ARV drugs on this stress response. This is the first re-
port showing UPR-related protein expression in HIV tar-
get cells derived directly from HIV-infected patients
receiving different ARV therapies. Here, we specifically
report that HIV infection is itself responsible for activat-
ing stress-response components and that ARV therapy
contributes to a change in the UPR pathway activation
profile based on both in vitro and in vivo analyses.
Results
HIV induces BiP expression
To determine whether HIV infection induces the cha-
perone BiP, PBMCs were infected with HIV and then sub-
mitted to different ARV treatments (Fig. 1a). The HIV
replication in PBMCs from normal donors under different
conditions is shown in Additional file 1: Table S1. Fur-
thermore, non-infected cells were submitted to the same
ARV treatment conditions to identify any pharmacological
modulation of UPR activation. The drugs selected for thisstudy, which were lamivudine (3TC), a nucleoside reverse
transcriptase inhibitor, and ritonavir (RTV), a protease in-
hibitor, were used separately or together. The Western blot-
ting results and further densitometry analysis show that the
ARV drugs used did not themselves induce any significant
effect on BiP expression in either non-infected or infected
clusters. However, infected cells without treatment or
under ARV treatment showed significantly higher expres-
sion of this chaperone in comparison with non-infected
cells, as demonstrated by the densitometry analysis.
The same profile of BiP expression was found when
in vivo assays were performed using cells from volunteers
(Fig. 1b). Both in monocyte- and in CD4+ T lymphocyte-
enriched populations, the control group, represented by
cells from healthy blood donors, showed lower expression
of BiP. In contrast, increased expression of this chaperone
was observed in HIV-infected cells, and, as already observed
in the in vitro assays, the type of ARV therapy did not ap-
pear to be a determinant of the induction of BiP expression.
In monocytes from treatment-naïve HIV patients, BiP ex-
pression was significantly higher (p < 0.05). CD4+ T lym-
phocytes also presented significantly higher expression of
BiP in the treatment-naïve group, similar to expression in
cells obtained from HIV-infected patients under treatment
without a protease inhibitor (p < 0.05). These data suggest
that HIV infection is capable of inducing BiP expression
under both in vitro and in vivo conditions, potentially
resulting in an environment that favors continued protein
folding, which is a significant indication of UPR activation.
HIV promotes translational attenuation through eIF2α
activation
The expression of the phosphorylated form of eIF2α
(P-eIF2α) was analyzed under both in vitro and in vivo
conditions by Western blotting. Phosphorylation of eIF2α
represents its activation, leading to translational inhibition
inside the cell. Under these conditions only, certain spe-
cific genes related to the ER stress response do not have
their expression attenuated. Furthermore, eIF2α phos-
phorylation is a consequence of previous PERK activation,
suggesting activation of this UPR sensor. In the present
study, no difference in P-eIF2α levels was observed in
non-infected PBMCs, regardless of the ARV treatment.
However, HIV-infected PBMCs that were submitted to
ARV treatment showed significantly higher expression of
P-eIF2α compared with non-infected cells (Fig. 2a). Inter-
estingly, the highest expression of P-eIF2α was found in
cells treated only with ritonavir (p < 0.001) compared with
the other treatments (p < 0.05).
HIV infection was also shown to be an important fac-
tor contributing to higher levels of P-eIF2α in cells from
HIV patients (Fig. 2b). However, in contrast to what was
demonstrated in the in vitro assays, the expression of
this protein was not detected in non-infected cells from
Fig. 1 HIV increases BiP expression under both in vitro and in vivo conditions. The expression of the chaperone BiP (78 kDa) was determined by
Western blotting (bottom panels) using an anti-BiP antibody. Actin was used as a loading control. The intensity of the resulting bands was
measured using ImageJ, and the BiP/actin ratio is shown in the upper panels. Each lane shown in the Western blots is representative of cells
under the same infectious and pharmacological conditions in vitro or in vivo. The bars represent mean ± standard deviation (SD) of BiP expression
within each group. a PBMCs were infected with the HIV-1 R5 isolate Ba-L and maintained free of ARV drugs or incubated with a nucleoside
reverse transcriptase inhibitor (lamivudine/3TC) and/or a protease inhibitor (ritonavir/RTV) for 7 days, followed by harvesting to prepare protein
lysates. C = control (non-infected PBMCs); 3TC = PBMCs incubated with 3TC; RTV = PBMCs incubated with RTV. b Enriched monocytes or CD4+
T lymphocytes obtained from whole blood from patients/volunteers were used to produce protein lysates. C = control (blood donors), n = 10;
TN = the treatment-naïve patients, n = 7; TNPI = patients under ARV therapy without a protease inhibitor, n = 9; TPI = patients under ARV therapy
with a protease inhibitor, n = 9. *p < 0.05; **p < 0.01; ***p < 0.001
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monocyte-enriched subpopulation from HIV-infected
volunteers was not significantly higher than in the cells
from healthy controls, and the ARV treatment did not
seem to be a key factor for this expression. However, in
the CD4+ T lymphocyte subpopulation, the combination
of HIV infection and ARV therapy was shown to be im-
portant. In particular, the lymphocytes from HIV-
infected patients showed significantly higher expression
of P-eIF2α compared with the control group. In this
case, as was found in the in vitro assays with PBMCs,
the ARV therapy led to higher expression of eIF2α (p <
0.001) compared with expression in the healthy control
group (p < 0.05). A comparison between the in vitro and
in vivo results indicated similar dynamics of HIV infec-
tion, in which the virus itself seems to be responsible for
higher expression of P-eIF2α, but the presence of ARVdrugs was also significant. However, the ARV therapy it-
self was not sufficient to induce the phosphorylation of
eIF2α, as indicated by the in vitro assays. Therefore, in-
fected PBMCs treated with ARV drugs have a different
expression profile than non-infected treated PBMCs do.
HIV can induce higher levels of IRE1 phosphorylation and
activation
PBMCs from healthy volunteers were submitted to HIV
infection under different ARV treatment conditions,
and the expression of the phosphorylated form of IRE1
(P-IRE1), one of the major sensors of the UPR pathway,
was analyzed. As for eIF2α, the phosphorylation of
IRE1 also represents its activation. One of the most im-
portant downstream effects of IRE1 activation is the
splicing of XBP1 mRNA, which, in this condition, will
be translated as an important transcription factor that
Fig. 2 HIV triggers eIF2α phosphorylation. The expression of the transcription factor eIF2α in its phosphorylated form (42 kDa) was determined by
Western blotting (bottom panels) using an anti-P-eIF2α antibody. Actin was used as a loading control. The intensity of the resulting bands was
measured using ImageJ, and the P-eIF2α/actin ratio is shown in the upper panels. Each lane shown in the Western blots is representative of cells
under the same infectious and pharmacological conditions in vitro or in vivo. The bars represent mean ± standard deviation (SD) of P-eIF2α
expression with each group. a PBMCs were infected with the HIV-1 R5 isolate Ba-L and maintained free of ARV drugs or incubated with a
nucleoside reverse transcriptase inhibitor (lamivudine/3TC) and/or a protease inhibitor (ritonavir/RTV) for 7 days, followed by harvesting to prepare
protein lysates. C = control (non-infected PBMCs); 3TC = PBMCs incubated with 3TC; RTV = PBMCs incubated with RTV. b Enriched monocytes
or CD4+ T lymphocytes obtained from whole blood from patients/volunteers were used to produce protein lysates. C = control (blood donors),
n = 10; TN = the treatment-naïve patients, n = 7; TNPI = patients under ARV therapy without a protease inhibitor, n = 9; TPI = patients under ARV
therapy with a protease inhibitor, n = 9. *p < 0.05; ***p < 0.001
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the present study, in in vitro assays, HIV infection was
able to induce P-IRE1 expression in PBMCs, regardless
of the presence or absence of ARV drugs (Fig. 3a).
However, this upregulation of P-IRE1 was significantly
higher when the cells were incubated with ARV drugs.
Curiously, in this case, treatment restricted to lamivu-
dine was shown to lead to higher expression of P-IRE1
(p < 0.01) than treatment with ritonavir did (p < 0.05).
As observed in the in vitro assays, P-IRE1 expression
levels in monocytes and CD4+ T lymphocytes from
HIV-infected patients were higher compared with levels
in cells obtained from healthy individuals (Fig. 3b). Des-
pite the change in the protein expression profile of the
infected cells relative to the control group, in which the
expression of P-IRE1 was not detected, the expression of
this protein was significantly higher only in CD4+ T lym-
phocytes from patients under ARV therapy (p < 0.001).A comparison between the in vitro and in vivo condi-
tions again shows that HIV infection upregulated the ex-
pression of P-IRE1 but that there was also a synergistic
effect of the ARV drugs. The results presented here cor-
roborate previous reports showing that protease inhibi-
tors trigger the UPR and also present new evidence that
other drugs, such as the nucleoside transcriptase inhibi-
tor used in this work, can lead to activation of this
pathway.
ATF6 is cleaved in HIV-infected cells
ATF6 is one of the three major sensors of the UPR path-
way, and it is activated after cleavage that occurs in the
Golgi apparatus. Cleaved ATF6 is a transcription factor
that leads to increased expression of UPR-related genes,
including the gene encoding the chaperone BiP. In the
current study, Western blotting assays were performed
with an antibody capable of detecting the cleaved and
Fig. 3 IRE1 shows higher activation in HIV-infected cells. The expression of the UPR sensor IRE1 in its phosphorylated form (100 kDa) was
determined by Western blotting (bottom panels) using an anti-P-IRE1 antibody. Actin was used as a loading control. The intensity of the resulting
bands was measured using ImageJ, and the P-IRE1/actin ratio is shown in the upper panels. Each lane shown in the Western blots is representative
of cells under the same infectious and pharmacological conditions in vitro or in vivo. The bars represent mean ± standard deviation (SD) of P-IRE1
expression in each group. a PBMCs were infected with the HIV-1 R5 isolate Ba-L and maintained free of ARV drugs or incubated with a nucleoside
reverse transcriptase inhibitor (lamivudine/3TC) and/or a protease inhibitor (ritonavir/RTV) for 7 days, followed by harvesting to prepare protein lysates.
C = control (non-infected PBMCs); 3TC = PBMCs incubated with 3TC; RTV = PBMCs incubated with RTV. b Enriched monocytes or CD4+ T lymphocytes
obtained from whole blood from patients/volunteers were used to produce protein lysates. C = control (blood donors), n = 10; TN = the treatment-naïve
patients, n = 7; TNPI = patients under ARV therapy without a protease inhibitor, n = 9; TPI = patients under ARV therapy with a protease inhibitor, n = 9.
*p < 0.05; **p < 0.01; ***p < 0.001
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assays, a larger amount of ATF6 was cleaved when cells
were infected with HIV, and ARV therapy did not sig-
nificantly affect the expression profile of this protein. In
particular, the expression of cleaved ATF6 in HIV-
infected PBMCs was significantly higher (p < 0.05) com-
pared with expression in non-infected PBMCs (Fig. 4a).
Monocytes from HIV-infected patients showed higher,
but not statistically significantly higher, expression of the
cleaved form of ATF6 compared with monocytes from
healthy individuals (Fig. 4b). A similar phenotype was
observed in CD4+ T lymphocytes, although the expres-
sion of cleaved ATF6 was significantly higher in cells
from HIV-infected patients. Moreover, treatment-naïve
patients showed slightly higher expression of this protein
(p < 0.001) compared with patients under ARV therapy
without a protease inhibitor (p < 0.05) or with a proteaseinhibitor (p < 0.01). These ATF6 cleavage results from
both the in vitro and the in vivo assays suggest that HIV
is responsible for the activation of this UPR pathway
sensor.
Discussion
Aiming to contribute to a better understanding of the
UPR activation caused by HIV, this study focused on
HIV target cells under variable ARV treatment settings
under both in vitro and in vivo conditions.
A general increase in BiP expression was observed in
in vitro HIV-infected PBMCs as well as in CD4+ T cells
and monocytes from HIV patients (Fig. 1). BiP is an ER
chaperone involved in protein folding and also in UPR
activation [15]. Certain viral infections have already been
reported to lead to increased BiP expression, including
members of the Flaviviridae family, such as dengue
Fig. 4 The cleaved form of ATF6 has higher expression in HIV-infected cells. The expression of the uncleaved (90 kDa) and cleaved (50 kDa) ATF6
molecules was determined by Western blotting (bottom panels) using anti-ATF6 antibodies. Actin was used as a loading control. The intensity of
the resulting bands was measured using ImageJ, and the cleaved ATF6/actin ratio is shown in the upper panels. Each lane shown in the Western
blots is representative of cells under the same infectious and pharmacological conditions in vitro or in vivo. The bars represent mean ± standard
deviation (SD) of of the expression of the cleaved form in each group. a PBMCs were infected with the HIV-1 R5 isolate Ba-L, maintained free of
ARV drugs or incubated with a nucleoside reverse transcriptase inhibitor (lamivudine/3TC) and/or a protease inhibitor (ritonavir/RTV) for 7 days,
followed by harvesting to prepare protein lysates. C = control (non-infected PBMCs); 3TC = PBMCs incubated with 3TC; RTV = PBMCs incubated
with RTV. b Enriched monocytes or CD4+ T lymphocytes obtained from whole blood from patients/volunteers were used to produce protein
lysates. C = control (blood donors), n = 10; TN = the treatment-naïve patients, n = 7; TNPI = patients under ARV therapy without a protease
inhibitor, n = 9; TPI = patients under ARV therapy with a protease inhibitor, n = 9. *p < 0.05; **p < 0.01; ***p < 0.001
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HCV [19], in addition to CMV [20] and enterovirus 71
(EV71) [21]. Higher BiP expression is a strong indication
of ER stress and the need for better folding capacity via
UPR activation [1]. In the present study, the absence of
significant differences in BiP expression between cells
free of pharmacological treatment and ARV-treated cells
and the lack of a significant impact of the ARV drugs
themselves on non-infected cells strongly suggest that
HIV was solely responsible for the stress observed in the
ER. In the case of infected cells from patients under
ARV therapy, despite their undetectable viral loads, the
permanence of stress is probably related to the continu-
ous presence of pro-inflammatory cytokines present
under these pharmacological conditions [22].
As found for BiP, ATF6 showed higher expression of
its activated form in HIV-infected cells, regardless of
the pharmacological conditions (Fig. 4). Activated ATF6
leads to higher expression of protein folding-related
genes, such as BiP [23]. ATF6 activation has alreadybeen described in cells infected with EBV [24], HCV
[19], DENV [17], lymphocytic choriomeningitis virus
(LCMV) [25], or WNV [18]. Considering the role of
ATF6 as a transcriptional activator of BiP expression, it
is reasonable to relate the greater abundance of its
cleaved state in infected cells to the consequent increase
in BiP expression to enhance the protein-folding capabil-
ity of the ER lumen [26].
The other UPR sensors, P-eIF2α and IRE1, showed dif-
ferent expression profiles than those observed for BiP
and ATF6. For these two molecules, the pharmacological
conditions seemed to be an important factor in modify-
ing protein expression profiles between different cell
groups (Figs. 2 and 3). More specifically, a tendency to-
ward increased expression of P-eIF2α was observed in
non-infected PBMCs treated with the protease inhibitor
RTV, regardless of the presence of a second drug, com-
pared with cells not submitted to ARV drugs. In
addition, when non-treated infected PBMCs were com-
pared with non-treated cells from the non-infected
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ever, for both comparisons, the differences were not
significant. Among HIV-infected PBMCs, significantly
higher expression of P-eIF2α was found in cells submit-
ted to ARV-mediated pharmacological control. Under
in vivo conditions, CD4+ T lymphocytes had significantly
higher expression of P-eIF2α than did monocytes, par-
ticularly among the cells obtained from patients un-
dergoing ARV treatment. This scenario is interesting
because when PERK phosphorylates eIF2α, the latter fac-
tor is deactivated. Simultaneously, eIF2α phosphoryl-
ation also increases translation of ATF4, which induces
expression of several UPR-related genes, including BiP.
These event leads to an attenuation of protein transla-
tion, decreasing the load of new proteins to be folded in
the ER lumen [27].
Accumulation of the phosphorylated form of eIF2α in
infected cells must be considered as a strategy to avoid
an excess of proteins to be folded in the ER lumen.
Caselli et al. have previously suggested that P-eIF2α can
promote a favorable environment for HIV replication
[10]. The presence of P-eIF2α may also lead to virus re-
activation from reservoirs, such as gut lymphoid tissues.
Considering the role of P-eIF2α in disrupting HIV la-
tency, the results obtained from patients undergoing
ARV therapy suggest a propitious environment for HIV
according to its described role in previous studies, which
is an unexpected perspective on cells under pharmaco-
logical control. Nevertheless, it is already known that
ARV drugs are capable of inducing ER stress and UPR
activation, which raises the possibility that this higher
UPR activation signal in treated cells compared with
cells without treatment is due to pharmacological UPR
activation.
The different expression profiles between monocytes
and CD4+ T lymphocytes could be related to discrepan-
cies in the HIV replication cycle between the two cell
types. It is well known that monocytes and macrophages
are very resistant to HIV infection and its cytopathic ef-
fects in comparison with CD4+ T lymphocytes [28]. This
refractory behavior favors latency and the role of mono-
cytes and macrophages as reservoirs [29]. Even in pa-
tients with no detectable viral load, it is possible to
recover and reactivate HIV replication in these cell types
[30]. Considering that HIV plays a role in eIF2α phos-
phorylation, the lack of significant eIF2α expression in
monocytes may be related to the less efficient HIV repli-
cation in these cells. In contrast, activated CD4+ T lym-
phocytes are the most permissive cellular target of HIV,
and when infected, these cells can die through caspase-
3-dependent apoptosis [31]. However, the frequency of
infected lymphocytes under clinical conditions is rela-
tively low, as permissive CD4+ T lymphocytes represent
less than 5 % of the whole lymphocyte population [32].These data suggest that the progressive loss of CD4+ T
lymphocytes can occur through other mechanisms. In
fact, it has already been described that approximately
95 % of the cell death in HIV patients occurs through a
caspase-1-dependent and highly inflammatory mechan-
ism called pyroptosis, which happens in less permissive
cells [33]. A highly inflammatory environment is estab-
lished even in patients submitted to ARV therapy and
with undetectable viral loads [22]. From the beginning
of an HIV infection, there is a massive depletion of
memory CD4+ T lymphocytes in the gastrointestinal
mucosa [34]. This depletion facilitates the translocation
of microbial products from the gut to the blood and
creates a constant source of immune activation and
inflammation that persists after ARV treatment [35].
Therefore, CD4+ T lymphocytes in HIV patients are
under constant metabolic stress, and the presence of
P-eIF2α is an indication of this condition.
As mentioned before, in the current study, P-IRE1 ex-
pression showed a similar profile to P-eIF2α expression
(Fig. 3). IRE1 in its phosphorylated form indicates acti-
vation of this UPR sensor [36]. As IRE1 is responsible
for the selective splicing of XBP1 mRNA (generating
sXBP1), it is expected that IRE1 activation leads to a
higher amount of sXBP1 and further expression of
protein degradation-related genes [37], decreasing the
protein-folding workload in the ER. IRE1 phosphoryl-
ation has already been described in avian coronavirus in-
fectious bronchitis virus (IBV) [38], EBV [24], CMV
[39], HCV [40], DENV-1 [17], and WNV [18] infections.
The state of protein degradation created by P-IRE1 in
the cell is not advantageous for viral replication. To
evade this cellular stress response, certain viruses, such
as CMV and HCV, can suppress the activity of sXBP1
and avoid the induction of its target genes [39, 40]. In
IBV-infected cells, IRE1 activation serves as a survival
factor during coronavirus infection, protecting cells from
apoptosis [38]. The higher expression of P-IRE1 in
treated patients with undetectable viral loads and the
lower expression in treatment-naïve individuals observed
in the current study are in agreement with activation of
the IRE1 sensor serving as a cellular defense mechanism.
However, further studies are necessary to elucidate
whether HIV also employs strategies to prevent possible
losses of its replication under these conditions.
The entire scenario of UPR activation presented in this
study revealed higher expression of ATF6 and BiP in
PBMCs as well in cells from patients, regardless of ARV
treatment, whereas activation of the other two UPR sen-
sors, PERK and IRE1, was ARV treatment dependent
(Fig. 5). For infected cells not submitted to ARV therapy,
ATF6 and BiP presented higher expression levels. For in-
fected cells under ARV treatment, including PBMCs cul-
tured in vitro and monocytes/CD4+ T lymphocytes from
Fig. 5 The UPR is activated in HIV-infected cells. The expression of BiP and cleaved ATF6 is increased in HIV-infected cells, regardless of ARV
therapy. Additionally, the PERK-related factor eIF2α and the sensor IRE1 are phosphorylated in HIV-infected cells under ARV treatment conditions.
Phosphorylation and activation of these molecules are known to lead, respectively, to selective translation of ATF4 and XBP1 splicing, both
contributing to a higher protein-folding capacity in the ER
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were present, triggering the activation of the three path-
way sensors PERK, represented by P-eIF2α, ATF6 and
IRE1. These results suggest that in an environment with
active HIV replication, the UPR pathway is modulated
by the virus, although the exact mechanisms are not
completely understood.
Conclusions
The results presented here indicate that HIV affects
UPR activation through its three major sensors: PERK,
IRE1, and ATF6. HIV-infected cells upregulate these
UPR-related proteins in a way that seems to be in-
dependent of the ARV treatment to which they are sub-
mitted. However, a synergistic pharmacological effect
appears to occur, as the drugs do not show the same in-
fluence on the protein expression profile of non-infected
cells under both in vitro and in vivo conditions. These
findings suggest two possible concurrent mechanisms:
the interference of HIV itself and the pharmacological
effects of the ARV drugs, both acting as activators of the
UPR. This report presents new evidence of how HIV
modulates the UPR pathway to enhance its ownreplication and secure infection success, and also raises
the promising possibility of using this pathway as a drug
target in the development of new antiviral therapies.
Methods
Ethics statement
This study was approved by the Internal Review Board
of Centro de Hematologia e Hemoterapia de Santa Catarina
(HEMOSC, Florianópolis, Brazil), Hospital Regional Dr.
Homero de Miranda Gomes (HRHMG, São José, Brazil),
and Centro de Testagem e Aconselhamento (CTA, São
José, Brazil) and by the Ethical Committees of Universidade
Federal de Santa Catarina (UFSC, Florianópolis, Brazil)
and Fundação Oswaldo Cruz (FIOCRUZ, Rio de Janeiro,
Brazil). All study subjects provided written informed con-
sent prior to enrollment.
Study population
The study sample consisted of 35 individuals. Eligible
volunteers included individuals over18 years old who
were recruited at HEMOSC, HRHMG, and CTA. The
individuals were selected from April 2011 to July 2012.
The volunteers were then arranged into four distinct
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treatment-naïve HIV-positive patients (TN) (n = 7; mean
viral load: 3.5 ± 0.7 log10 copies/ml), iii) HIV-positive pa-
tients under ARV therapy without a protease inhibitor
(TNPI) (n = 9; undetectable viral load), and iv) HIV-
positive patients under ARV therapy including a protease
inhibitor (TPI) (n = 9; undetectable viral load). Infections
by Epstein-Barr virus (EBV), cytomegalovirus (CMV),
hepatitis C virus (HCV), herpes simplex 1 virus (HSV-1),
or human herpes virus 8 (HHV-8), or any other acute in-
fections were considered as exclusion criteria for any of
the groups described. The clinical data from the HIV-
positive patients were accessed through their medical
records.
Sample collection and processing
For the in vivo assays, whole-blood samples from the en-
rolled volunteers were collected in EDTA tubes. CD4+ T
lymphocytes and monocytes were then isolated from
peripheral blood mononuclear cells (PBMCs) using the
RosetteSep Human CD4+ T Cell Enrichment Cocktail
and RosetteSep Human Monocyte Enrichment Cocktail
kits (STEMCELL Technologies), respectively. The cell
purity was determined using fluorochrome-labeled anti-
CD3, anti-CD4, and anti-CD14 antibodies (BD Pharmin-
gen), a FACSCalibur flow cytometer (Becton Dickinson),
and the software FlowJo 8.6.3 (© Tree Star) (Additional
file 2: Figure S1).
HIV infection assay
PBMCs from 3 healthy donors were obtained by density
gradient centrifugation (Hystopaque, Sigma) of buffy-coat
preparations. These PBMCs were resuspended in RPMI
1640 (LGC Bio) supplemented with 10 % heat-inactivated
fetal bovine serum (FBS; HyClone, Logan, UT), penicillin
(100 U/mL), streptomycin (100 μg/mL), 2 mM glutamine
and 10 mM HEPES, followed by stimulation with 5 μg/mL
phytohemagglutinin (PHA; Sigma) for 2–3 days and fur-
ther maintenance in culture medium containing 5 U/mL
recombinant human interleukin-2 (Sigma). The PBMCs
were then infected with the HIV-1 R5 isolate Ba-L using
5–10 ng/mL p24 antigen. After 2 h of incubation, the cells
were washed to remove excess virus. Culture medium was
added to the infected PBMCs, followed by treatment with
ARV drug(s), which lasted throughout the infection
period. Next, HIV-1 replication was evaluated in the cell
culture supernatants 7 days after infection using a com-
mercial ELISA kit (ZeptoMetrix Co.). The cells were di-
vided into 4 groups: i) untreated cells, ii) cells treated with
a nucleoside reverse transcriptase inhibitor (lamivudine/
3TC, 1 μM), iii) cells treated with a protease inhibitor
(ritonavir/RTV, 10 μM), and iv) cells treated with 3TC +
RTV. Additionally, non-infected cells submitted to the 4
different conditions described were used as controls.Preparation of cellular protein lysates
Cellular protein lysates were prepared from 1 × 106 CD4+
T lymphocytes or monocytes from enriched subpopulations
using the Ambion® PARIS™ system (Life Technologies). A
protease inhibitor cocktail (Sigma-Aldrich) was added to
the resulting lysates, which were then stored at −20 °C. For
the in vitro assays, the PBMCs were suspended in a lysis
buffer composed of 20 mM Tris–HCl, pH 7.5, and a prote-
ase and phosphatase inhibitor cocktail (Sigma-Aldrich).
After incubation for 10 min at 4 °C, followed by centrifuga-
tion (20,000 × g, 10 min, 4 °C), the supernatants were col-
lected and stored at −70 °C. Protein quantification was then
performed via the bicinchoninic acid (BCA) method using
a Micro BCA Protein Assay Kit (Pierce), with the actual
measurement performed by spectrophotometry at 562 nm
using an Infinite M200 microplate reader (Tecan).
Western blotting
In total, 10 μg of each cellular protein lysate sample was
separated by 12 % SDS-PAGE and electro-blotted onto a
nitrocellulose membrane (GE Healthcare) soaked with
blotting buffer (25 mM Tris, 192 mM glycine, and 20 %
methanol, pH 8.3). Subsequently, the membranes were
incubated for 1 h at 25 °C with rabbit anti-actin (ab8227,
Abcam), mouse anti-BiP (ab96483, Abcam), rabbit anti-
P-eIF2α (ab4837, Abcam), rabbit anti-P-IRE1 (ab48187,
Abcam), or mouse anti-ATF6 (ab11909, Abcam). The
blots were then incubated with an HRP-conjugated anti-
mouse or anti-rabbit total immunoglobulin (respectively,
ab6728 or ab6721, Abcam) for 1 h at 25 °C. The detec-
tion was performed using the ECL reagent (Pierce) and
exposure to radiographic films (GE Healthcare), the de-
velopment of which was performed using an automated
SRX-101A processor (Konica Minolta).
Protein expression evaluation by densitometry
Quantitative analysis of the data obtained from the Western
blotting experiments was performed by band densitometry
using the software ImageJ (http://rsbweb.nih.gov/ij/).
Statistical analysis
The data were presented as mean ± standard deviation
(SD). The results were plotted and submitted to statis-
tical analysis through the ANOVA parametric test. Ob-
servations were considered statistically significant when
p < 0.05. The statistical analyses were performed using
the software GraphPad InStat®, and the graphs were
drawn with GraphPad Prism, version 5.
Additional files
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